분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2017-02-16 09:52:40 , Hit : 954
 Judges Side with Broad Institute in CRISPR Patent Dispute

http://www.genengnews.com/gen-news-highlights/judges-side-with-broad-institute-in-crispr-patent-dispute/81253890?utm_medium=newsletter&utm_source=GEN+Daily+News+Highlights&utm_content=01&utm_campaign=GEN+Daily+News+Highlights_20170215


GEN News Highlights

February 15, 2017

A three-judge panel of the Patent Trial and Appeal Board (PTAB) has ruled in favor of the Broad Institute of MIT and Harvard in the bitter legal battle royal with University of California (UC), Berkeley, over who invented CRISPR (clustered regularly interspaced short palindromic repeats) gene-editing technology.

The PTAB panel found “no interference in fact” between 12 patents related to CRISPR technology that list as inventor Feng Zhang, Ph.D., of the Broad Institute, and a patent application by Jennifer Doudna, Ph.D., of UC Berkeley, and Emmanuelle Charpentier, Ph.D., of the Helmholtz Centre for Infection Research.

As a result, the application can be returned to the U.S. Patent and Trademark Office (USPTO) examiner who previously determined it allowable for review.

The Doudna/Charpentier application states claims covering the use of CRISPR in a bacterial system, while the Broad's patents focus on the use of CRISPR in eukaryotic systems, such as plants and higher animals. UC Berkeley, Dr. Doudna, and Dr. Charpentier challenged the Broad patents, contending that the application of CRISPR to eukaryotic systems represented an obvious rather than an inventive invention, and was thus nonpatentable. The Broad has defended its patents.

“This evidence shows that the parties’ claims do not interfere. Accordingly, we terminate the interference,” the PTAB panel ruled. “The evidence shows that the invention of such systems in eukaryotic cells would not have been obvious over the invention of CRISPR/Cas9 systems in any environment, including in prokaryotic cells or in vitro, because one of ordinary skill in the art would not have reasonably expected a CRISPR/Cas9 system to be successful in an eukaryotic environment.”

In a statement, Broad emphasized the potential of CRISPR technology to generate far more patents than those at issue in the legal dispute.

“CRISPR research is a very large field that involves contributions from talented scientists around the world. We have deep respect for all of these scientific contributions, including the work from Emmanuelle Charpentier, Jennifer Doudna, and their teams, as well as all of those who continue to advance the field and educate the public about this important technology,” Broad stated.

Broad said it would continue to work with partner organizations “to disseminate and share CRISPR genome-editing tools to maximize public benefit, especially by continuing to make this transformative technology widely available to the worldwide academic community and for commercial and human therapeutic research.

“We believe CRISPR should continue to be available to the global scientific community to advance our understanding of the biology and treatment of human disease, and to help lay the groundwork for a new generation of therapies,” Broad added.

The PTAB panel heard oral arguments in December when it considered whether an “interference” proceeding aimed at resolving the impasse could proceed, as declared in January by Administrative Patent Judge Deborah Katz of the USPTO.

In its own statement, UC Berkeley continued to maintain that evidence “overwhelmingly” supports its position that the team of Drs. Doudna and Charpentier was the first group to invent the technology for use in all settings and all cell types. It continues to assert that the team was the first to publish and file patent applications directed toward that invention, and that the Broad Institute’s patents were not patentably distinct from the Doudna/Charpentier invention.

“For that reason, UC will carefully consider all options for possible next steps in this legal process, including the possibility of an appeal of the PTAB’s decision,” UC Berkeley stated. “We will be guided, as always, by the public’s best interest and will continue to support and advance fundamental research, such as CRISPR/Cas9, that can help solve our greatest challenges across human health, agriculture, and the environment.”

Editas Medicine—whose co-founders include Drs. Zhang and Doudna—hailed the PTAB panel decision in a statement lauding Broad’s “innovative and fundamental work” on CRISPR technology. Editas was launched in 2013 to translate their genome editing research into new therapeutics

“This important decision affirms the inventiveness of the Broad’s work in translating the biology of the natural world into fundamental building blocks to create unprecedented medicines,” stated Katrine Bosley, president and CEO of Editas. “We are continuing to invest in this technology to build our business for the long-term and to create genome-editing therapies for patients suffering from genetically-defined and genetically-treatable diseases.”







1007   CRISPR Platform Scans DNA to Predict Off-Target Effects  이성욱 2017/07/02 1128
1006   Fixing CRISPR  이성욱 2017/06/27 1006
1005   [미국] 듀폰, 유전자가위 기술 적용 옥수수 출시를 위한 노력  이성욱 2017/06/22 914
1004   [바이오토픽] CRISPR를 역이용하는 파지(phage), 항생제내성 세균을 물리치는 신무기  이성욱 2017/06/22 1169
1003   [바이오 업계 소식: From Startups to Moguls] CRISPR-Cas9에 대한 경고와 업계 반응  이성욱 2017/06/14 698
1002   Was a Drop in CRISPR Firms’ Stock Warranted?  이성욱 2017/06/09 1209
1001   First In Vivo Human Genome Editing to Be Tested in New Clinical Trial  이성욱 2017/05/18 769
1000   독감바이러스의 ‘RNA 도둑질’  이성욱 2017/05/08 805
999   More Tooth, More Tail in CRISPR Operations  이성욱 2017/04/25 903
998   Gut Microbes Contribute to Age-Associated Inflammation in Mice  이성욱 2017/04/14 1394
997   CRISPR Corrects Duchenne-Causing Mutations  이성욱 2017/04/14 841
996   Scientists unveil CRISPR-based diagnostic platform  이성욱 2017/04/14 813
995   [사이언스 카페] 美 FDA, 민간업체의 '개인용 유전자 검사' 첫 허용  이성욱 2017/04/10 798
994   암 전이에 핵심 역할하는 줄기세포 찾았다  이성욱 2017/04/03 1164
993   ‘단세포 인공생명체’ 눈앞에 성큼  이성욱 2017/03/11 796
992   Beyond CRISPR Cuts: Five Complements To Cas9  이성욱 2017/02/24 987
991   Smallest CRISPR So Far Comes from Food Poisoning Bacteria  이성욱 2017/02/24 925
990   CRISPR Turbocharges CAR T Cells, Boosts Cancer Immunotherapy  이성욱 2017/02/24 1291
989   [바이오토픽] 브로드 연구소, 열띤 CRISPR 특허전쟁에서 승리  이성욱 2017/02/16 1060
  Judges Side with Broad Institute in CRISPR Patent Dispute  이성욱 2017/02/16 954

[이전 10개] [1]..[11][12][13] 14 [15][16][17][18][19][20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN